Promis Neurosciences INC

ProMIS Neurosciences announced positive blinded interim safety and biomarker data for its Alzheimer's drug candidate, PMN310, showing no ARIA-E and encouraging biomarker trends.

ProMIS Neurosciences announced its first quarter 2026 financial results, highlighting the closure of a significant financing round and progress in its Phase 1b Alzheimer's disease trial.

ProMIS Neurosciences announced its full year 2025 financial results and provided a corporate update, highlighting significant progress in its Alzheimer's disease clinical trial and securing substantial financing.

ProMIS Neurosciences Inc. announced a private placement financing of up to $175 million, extending its cash runway into 2028 and funding key clinical milestones for its Alzheimer's drug candidate.

ProMIS Neurosciences Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously disclosed deficiency matter.

ProMIS Neurosciences Inc. announced a one-for-twenty-five reverse stock split to take effect on November 28, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement.

ProMIS Neurosciences Inc. reported its first quarter 2026 financial results, highlighting significant progress in its Alzheimer's drug candidate PMN310 and a substantial increase in cash reserves following a successful private placement.

ProMIS Neurosciences reported a significant net loss in Q3 2025, raising capital through warrant exercises and offerings, but faces substantial doubt about its ability to continue as a going concern.

ProMIS Neurosciences reported increased net losses and negative working capital for Q2 2025, but subsequently secured $21.6 million in gross proceeds to support ongoing operations and clinical trials.

ProMIS Neurosciences reports a net loss of $7.3 million for Q1 2025 and highlights the ongoing Phase 1b clinical trial for PMN310 in Alzheimer's disease.

ProMIS Neurosciences reported its Q3 2024 financial results, highlighting progress in its PMN310 clinical trial and a significant private placement.

ProMIS Neurosciences reported its second quarter 2024 financial results, highlighted by progress in its PMN310 clinical trial and a recent $30.3 million private placement.

ProMIS Neurosciences reports significant progress in its lead Alzheimer's disease clinical trial, PMN310, and strengthens its financial position with recent capital raises.

ProMIS Neurosciences reports ongoing losses in its 2024 10-K filing while highlighting progress in clinical trials for Alzheimer's disease and preclinical development for ALS and MSA therapies.

ProMIS Neurosciences' 2023 annual report highlights progress in clinical trials for PMN310, along with continued development of its pipeline targeting neurodegenerative diseases.

Director William Wyman was granted 16,500 stock options in ProMIS Neurosciences Inc. as part of board compensation.

Director Eugene Williams was granted options to purchase 16,500 common shares of ProMIS Neurosciences Inc.

CEO Neil Warma was granted 160,000 stock options in ProMIS Neurosciences with an exercise price of $10.77.

Director Madge K. Shafmaster was granted 16,500 stock options in ProMIS Neurosciences Inc. as part of board compensation.

Chief Scientific Officer Neil Cashman was granted 50,000 stock options in ProMIS Neurosciences, vesting over four years.

Principal Accounting Officer Max A. Milbury was granted 18,167 stock options in ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. has announced its 2026 Annual Meeting of Shareholders will be held virtually on May 20, 2026, to elect directors, ratify auditors, and approve a stock plan amendment.

PROMIS Neurosciences Inc. will hold a Special Meeting on November 17, 2025, to vote on a share consolidation proposal ranging from one-for-five to one-for-twenty-five.

ProMIS Neurosciences Inc. will hold a Special Meeting on November 17, 2025, for shareholders to vote on a share consolidation to meet Nasdaq's minimum bid price requirement.

Promis Neurosciences Inc. will hold its annual shareholder meeting on June 12, 2025, with voting open until June 10, 2025, to elect directors, ratify the appointment of auditors, and approve the 2025 Stock Option and Incentive Plan.

ProMIS Neurosciences announces its 2025 Annual Meeting of Shareholders to be held virtually on June 12, 2025, featuring proposals for director elections, auditor ratification, and approval of a new stock option and incentive plan.

Promis Neurosciences Inc. is holding a special meeting on October 23, 2024, for shareholders to vote on a proposal related to the issuance of common shares and a potential adjournment of the meeting.

Ally Bridge Group and its affiliates, led by Fan Yu, increased their beneficial ownership in ProMIS Neurosciences Inc. to 17.0% following a recent offering and a reverse stock split.

Ally Bridge Group entities have increased their beneficial ownership in ProMIS Neurosciences Inc. to 11.3% through a new securities purchase agreement.

Ally Bridge Group entities and Fan Yu disclose an 11.3% beneficial ownership in ProMIS Neurosciences Inc. and the appointment of Slanix Paul Alex to the Board of Directors.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, has reported beneficial ownership of 9.99% of Promis Neurosciences Inc. common shares.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 10% of ProMIS Neurosciences, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 14.4% of Promis Neurosciences Inc. common shares as of March 31, 2026.

Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. has reported a 9.99% beneficial ownership stake in ProMIS Neurosciences, Inc. common stock.

Deep Track Capital and its affiliates have reported a 9.99% beneficial ownership stake in ProMIS Neurosciences Inc., including common shares and exercisable warrants.

Sphera Funds Management and its affiliates reported a 7.78% beneficial ownership stake in ProMIS Neurosciences Inc., including common shares and warrants, following a recent reverse stock split.